Akesis Pharmaceuticals (fka AKESQ)

[Renee]

AKESQ revoked:

http://www.sec.gov/litigation/admin/2015/34-74777.pdf

[Renee]

AKESQ SEC Suspension for delinquent Financials / filings:

http://www.sec.gov/litigation/suspensions/2015/34-74330.pdf

Order:

http://www.sec.gov/litigation/suspensions/2015/34-74330-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2015/34-74331.pdf

[TheInvincibleBull]

this could easily run to $1 imo

[kranthikumar]

AKESQ is smells like a winner

[narbi]

Who would be trading this?

[INDY]

SEC 10Q FILED 8/7/08:

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6085572

[INDY]

RECENT NEWS:

Akesis Pharmaceuticals Enters into Bridge Financing Transaction

SAN DIEGO, Sep 30, 2008 (BUSINESS WIRE) -- Akesis Pharmaceuticals, Inc. (OTCBB: AKES), an emerging diabetes drug-development company, today announced that, on September 29, 2008, it entered into a Note and Warrant Purchase Agreement with Avalon Ventures VII, L.P. Pursuant to the Note and Warrant Purchase Agreement, the Company has the ability to sell to Avalon Ventures one or more convertible promissory notes maturing February 1, 2009 in an aggregate principal amount of up to $2.0 million. Each note will automatically convert into shares of the Company's preferred stock in the event of the closing, prior to February 1, 2009, of a preferred stock financing resulting in aggregate gross proceeds to the Company of at least $2.0 million (including amounts received in connection with the conversion of the notes) and will be issued together with a five-year warrant to purchase additional shares of such preferred stock. An initial closing of the sale of notes and warrants was held on the Effective Date of the Note and Warrant Purchase Agreement and involved the sale to Avalon Ventures of a note (and a corresponding warrant) representing an initial principal amount of $1.0 million.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any security. The securities issued pursuant to the Note and Warrant Purchase Agreement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States absent registration under the Securities Act of 1933, as amended, and applicable state securities laws or an applicable exemption from registration requirements.

[INDY]

**DD**

Akesis Pharmaceuticals has a pipeline of innovative oral product candidates for the treatment of diabetes and related metabolic disorders. These product candidates are supported by issued and filed U.S. patents for both prescription and over-the-counter treatments that combine anti-diabetic trace minerals with certain classes of diabetes oral agents. Akesis' product candidates have demonstrated preliminary evidence of efficacy in lowering and controlling blood glucose levels in patients with Type 2 diabetes. Blood sugar control via oral drugs represents a market opportunity in the billions of dollars, as reports indicate that approximately 20 million people suffer from diabetes in the United States alone. More information can be found at www.akesis.com.

[INDY]

CONACT INFORMATION:

Akesis Pharmaceuticals, Inc.
888 Prospect Street
Suite 320
La Jolla , CA 92037
Phone: [phone]

[amit9898]

This is a good stock to keep an eye on!

[amit9898]

Whats going on with this stock? Any news coming

[Bane]

I know you guys were dopers! LMBSO!

[mick]

market doesn't know which way to go. i like the upticks.

[OptionMonster]

Heading north again Mick..AKES Bid: 0.55 Ask: 0.67 Last: 0.67 ($): 0.01 Vol: 7,878 |

[mick]

yes, fda is the key here.

[OptionMonster]

If they can just get one of those past the FDA mick..WOW!!$$

[mick]

small down ticks this morning.

Detailed Quote for Akesis Pharmaceuticals Inc. (AKES)
$ 0.60 -0.06 (-9.09%) Volume: 7.0 k 10:34 AM EST Nov 6, 2007

[OptionMonster]

$ 0.66 0.11 (+20.00%) Volume: 3.5 k 3:53 PM EST Nov 5, 2007

[mick]

i remember vcall back a few.


http://www.vcall.com/console/ConsoleFrameset.asp?ID=119909&brand=Vcall&ClickType=&playerID=1&urlID=124066&sessionID=87DF6862A97E41AF&email=[e-mail]&tck=AKES.OB

[OptionMonster]

http://www.vcall.com/console/ConsoleFrameset.asp?ID=119909&brand=Vcall&ClickType=&playerID=1&urlID=124066&sessionID=87DF6862A97E41AF&email=[e-mail]&tck=AKES.OB

[mick]

Detailed Quote for Akesis Pharmaceuticals Inc. (AKES)
$ 0.55 -0.13 (-19.12%) Volume: 966 9:30 AM EDT Nov 2, 2007

[mick]

hi leon, good afternoon. this could be a good one.

o/s aren't bad either.